NSC19630 | CAS#72835-26-8 | WRN helicase inhibito

MedKoo Cat#: 407982 | Name: NSC19630

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NSC19630, also known as MIRA-1, is a potent and selective WRN helicase inhibitor with activity against human normal and cancer cells via a caspase-9-dependent apoptosis.

Chemical Structure

NSC19630

CAS#72835-26-8

Theoretical Analysis

MedKoo Cat#: 407982

Name: NSC19630

CAS#: 72835-26-8

Chemical Formula: C8H9NO4

Exact Mass: 183.0532

Molecular Weight: 183.16

Elemental Analysis: C, 52.46; H, 4.95; N, 7.65; O, 34.94

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 250.00
50mg	USD 750.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

NSC19630; NSC-19630; NSC 19630; MIRA-1; MIRA1; MIRA 1;

IUPAC/Chemical Name

1-[(1-oxopropoxy)methyl]-1H-pyrrole-2,5-dione

InChi Key

YXEWPGYLMHXLPS-UHFFFAOYSA-N

InChi Code

InChI=1S/C8H9NO4/c1-2-8(12)13-5-9-6(10)3-4-7(9)11/h3-4H,2,5H2,1H3

SMILES Code

O=C(C=C1)N(COC(CC)=O)C1=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C20M11C19

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

MIRA-1 can induce apoptosis in mutant p53 cells via restoration of p53-dependent transcriptional transactivation.

In vitro activity:

This study tested whether MIRA-1 could induce mutant p53-dependent growth inhibition in human SKOV ovarian carcinoma or H1299 lung adenocarcinoma cells carrying His175 or His273 mutant p53 under control of the tetracycline promoter. In all three cell lines expressing mutant p53 under control of the tetracycline-dependent promoter this study observed mutant p53-dependent growth suppression similar to that seen in Saos-2-His273 cells. Reference: J Biol Chem. 2005 Aug 26;280(34):30384-91. https://pubmed.ncbi.nlm.nih.gov/15998635/

In vivo activity:

This study sought to examine whether in vitro MIRA-1-induced MM cytotoxicity can be translated into effective in vivo anti-MM activity in SCID mice xenografted 8226 cells. Treatment with MIRA-1 significantly retarded tumour growth, with maximum tumour growth inhibition noted at day 15 (Figure 6A) (P<0.05). MIRA-1 treatment was also associated with improved survival, evidenced by first death at day 20 in control versus day 45 in treated group (Figure 6B) (P=0.007). Reference: Br J Cancer. 2014 Apr 29;110(9):2224-31. https://pubmed.ncbi.nlm.nih.gov/24691427/

	Solvent	mg/mL	mM
Solubility
	DMSO	45.5	248.63
	Ethanol	18.3	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 183.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Bou-Hanna C, Jarry A, Lode L, Schmitz I, Schulze-Osthoff K, Kury S, Bezieau S, Mosnier JF, Laboisse CL. Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis. Cancer Lett. 2015 Apr 10;359(2):211-7. doi: 10.1016/j.canlet.2015.01.014. Epub 2015 Jan 21. PMID: 25617798. 2. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem. 2005 Aug 26;280(34):30384-91. doi: 10.1074/jbc.M501664200. Epub 2005 Jul 1. Erratum in: J Biol Chem. 2017 Dec 1;292(48):19607. PMID: 15998635. 3. Saha MN, Chen Y, Chen MH, Chen G, Chang H. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br J Cancer. 2014 Apr 29;110(9):2224-31. doi: 10.1038/bjc.2014.164. Epub 2014 Apr 1. PMID: 24691427; PMCID: PMC4007239.

In vitro protocol:

In vivo protocol:

1. Saha MN, Chen Y, Chen MH, Chen G, Chang H. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br J Cancer. 2014 Apr 29;110(9):2224-31. doi: 10.1038/bjc.2014.164. Epub 2014 Apr 1. PMID: 24691427; PMCID: PMC4007239.

1: Bou-Hanna C, Jarry A, Lode L, Schmitz I, Schulze-Osthoff K, Kury S, Bezieau S, Mosnier JF, Laboisse CL. Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis. Cancer Lett. 2015 Apr 10;359(2):211-7. doi: 10.1016/j.canlet.2015.01.014. Epub 2015 Jan 21. PubMed PMID: 25617798.